Sonrai Analytics
Belfast, United Kingdom
About
Sonrai Analytics is a Belfast AI and data-science company working in precision medicine, building machine-learning and computational-pathology systems for pharma and diagnostics clients on its own analysis platform.
Who They Work With
Diagnostics and pharma teams that need multi-omic and pathology data analyzed by named scientists, with a regulatory path in view.
Based on 3 client engagements with a source URL · researched 8 Sept 2026
Our Take
Two named clients describe the same practice from opposite ends: IV Bioholdings' CEO credits the engagement with turning legacy RNA-Seq and PCR data into a validated biomarker case, and Axis Bio's co-founder describes custom apps that replaced Excel for a preclinical CRO, with a traffic-light check flagging anomalies such as unexpected body-weight changes.
The regulated work is what separates this from general data science—AI IVD medical devices for MSI testing in colorectal cancer and PD-L1 tumour proportion scoring in non-small cell lung cancer, built with the Precision Medicine Centre at Queen's University under an NHS AI Award—but read the results section closely: the devices are described as ready for submission to a notified body, not yet CE-marked under IVDR.
Six people are named on the team page, four of them with doctorates, and delivery is described as scientist-led with no handoffs; the platform percentages quoted elsewhere on the site (52% faster biomarker discovery, 57% acceleration on mechanism-of-action studies) carry no client attached.
The weaker fit is anyone outside precision medicine: the whole practice is oncology, multi-omics and computational pathology, with no general-purpose AI delivery shown.
Key strengths
- Regulated-AI work is the practice rather than a claim: IVD devices for MSI and PD-L1 scoring built toward EU IVDR conformity assessment with Queen's University's Precision Medicine Centre
- Named client executives on the record—IV Bioholdings' CEO and Axis Bio's co-founder—each describing what the engagement changed
- Six named people on the team page, four with doctorates, and delivery described as scientist-led rather than handed to an account team
Good to know
- The IVD devices are described as ready for submission to a notified body, not approved—ask where each device sits in conformity assessment today
- Client outcomes are qualitative (investment case strengthened, client satisfaction); the percentage figures elsewhere are the platform's own claims—ask for a program with measured endpoints
- No rate is published and the team is 10-49—anchor on the European range on our rate index and ask how many programs run concurrently
Reviewed by Gabor Kiss
Founder & Curator, AIAgencies.eu · 8 Sept 2026
Based on the agency's publicly available portfolio. Own this agency? Claim your profile to provide additional context or request a review update.
Notable Clients
Every engagement documented in a published case study
Documented engagements: IV Bioholdings, Axis Bio, and Precision Medicine Centre, Queen's University Belfast. All 3 carry a source URL on file.
Services
Industries
Get Matched with Agencies
RecommendedTell us your needs and we'll connect you with 3 vetted agencies—including Sonrai Analytics if it's a fit.
Get Matched →Curator shortlist within 3 business days
Visit Sonrai Analytics's website →Own this agency? Claim your profile to verify info & receive leads directly.
